Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men
Int J Obes. 2007-01-16; 31(4): 692-699
DOI: 10.1038/sj.ijo.0803539
Lire sur PubMed
1. Int J Obes (Lond). 2007 Apr;31(4):692-9. doi: 10.1038/sj.ijo.0803539. Epub
2007 Jan 16.
Circulating endocannabinoid levels, abdominal adiposity and related
cardiometabolic risk factors in obese men.
Côté M(1), Matias I, Lemieux I, Petrosino S, Alméras N, Després JP, Di Marzo V.
Author information:
(1)Hôpital Laval Research Centre, Québec, Canada.
OBJECTIVE: The link between excess intra-abdominal adiposity (IAA) and metabolic
complications leading to type 2 diabetes and cardiovascular disease is well
recognized. Blockade of endocannabinoid action at cannabinoid CB(1) receptors
was shown to reduce these complications. Here, we investigated the relationship
between IAA, circulating endocannabinoid levels and markers of cardiometabolic
risk in male obese subjects.
DESIGN, SUBJECTS AND MEASUREMENTS: Fasting plasma levels of the
endocannabinoids, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), were
measured by liquid chromatography-mass spectrometry in a study sample of 62
untreated asymptomatic men with body mass index (BMI) from 18.7 to 35.2 kg/m(2).
RESULTS: Plasma 2-AG, but not AEA, levels correlated positively with BMI, waist
girth, IAA measured by computed tomography, and fasting plasma triglyceride and
insulin levels, and negatively with high-density lipoprotein cholesterol and
adiponectin levels. Obese men with similar BMI values (> or =30 kg/m(2)) but who
markedly differed in their amount of IAA (< vs > or = 130 cm(2), n=17) exhibited
higher 2-AG levels in the presence of high IAA. No difference in 2-AG
concentrations was observed between obese men with low levels of IAA vs nonobese
controls.
CONCLUSIONS: These results provide evidence for a relationship in men between a
key endocannabinoid, 2-AG, and cardiometabolic risk factors, including IAA.
DOI: 10.1038/sj.ijo.0803539
PMID: 17224929 [Indexed for MEDLINE]